Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme
{{output}}
Glioblastoma multiforme (GBM) defies the currently practiced management of radiotherapy, chemotherapy and surgery and hence, it is associated with a high fatality rate with a median survival of 14.6 months. In our previous work investigating different tyrosine... ...
